Sulfinpyrazone NEW
| Price | $58 |
| Package | 200mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Sulfinpyrazone | CAS No.: 57-96-5 |
| Purity: 98.1% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Sulfinpyrazone |
| Description | Sulfinpyrazone (NSC-75925) is a uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. |
| In vivo | Sulfinpyrazone exerts significant electrophysiologic actions under various experimental conditions. It raises the ventricular fibrillation threshold as well as the mid diastolic threshold and prolongs the effective refractory period. In the acutely ischemic heart, it attenuates the effect of coronary occlusion on the ventricular fibrillation threshold but has no effect after reperfusion. A protective influence of the drug is also evident during sympathetic humoral stimulation with norepinephrine. The antifibrillatory effect of sulfinpyrazone is additive to the changes elicited by beta adrenergic blockade with practolol or cardiac membrane stabilization with lidocaine[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | Ethanol : 64 mg/mL (158.23 mM) DMSO : 40 mg/mL (98.89 mM) |
| Keywords | gouty | G28315 | uricosuric | intermittent | antithrombotic | G 28315 | oral | Sulfinpyrazone | arthritis | platelet | NSC-75925 | inhibit | NSC75925 | Inhibitor |
| Inhibitors Related | Ibuprofen | Acetaminophen | Salicylamide | Diclofenac sodium | Diclofenac Potassium | Paradol | Indomethacin sodium hydrate | Trometamol | Glafenine | Revaprazan hydrochloride |
| Related Compound Libraries | FDA-Approved & Pharmacopeia Drug Library | Pain-Related Compound Library | Bioactive Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $58.00/200mg |
VIP5Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $10.00/25Kg/Drum |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2021-10-19 | |
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-06-16 | |
| $1.00/1KG |
VIP7Y
|
Career Henan Chemical Co
|
2018-08-20 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY